A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade. In clinical trials, ...
An inhalable drug treatment for chronic obstructive pulmonary disease received FDA-approval June 26, drugmaker Verona Pharma announced. It is the first FDA-approved treatment for COPD in more than two ...
David Mannino is co-founder and chief medical officer of the COPD Foundation. He's an internal medicine doctor with a specialty in pulmonary, critical care, and sleep medicine at University of ...
The FDA approved Ohtuvayre (ensifentrine) as a maintenance therapy for COPD (chronic obstructive pulmonary disease). The medication works as both a bronchodilator and an anti-inflammatory to ease ...
-Ritedose is the development partner and manufacturer of Ohtuvayre (ensifentrine)*, the first inhaled product with a novel mechanism of action in more than 20 years for the maintenance treatment of ...
Clinical Trials Arena on MSN
Mabwell’s mAb leads to 40% reduction in severe COPD exacerbations
A Chinese Phase IIb trial of the mAb has already started, with Mabwell also hoping to initiate a Phase IIa trial in the US.
Early detection and innovative biologic treatment can prevent hospitalizations, improve quality of life, and extend the ...
Inflammation that develops in chronic obstructive pulmonary disorder stems from different causes. A new regulatory decision in Europe makes Sanofi and Regeneron Pharmaceuticals drug Dupixent the first ...
Ensifentrine (Ohtuvayre), a novel medication for the treatment of chronic obstructive pulmonary disease (COPD) recently approved by the US Food and Drug Administration, has been shown to reduce COPD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback